89bio, Inc.
Clinical trials sponsored by 89bio, Inc., explained in plain language.
-
New drug aims to reverse liver scarring in MASH patients
Disease control Recruiting nowThis study tests a drug called pegozafermin in about 762 adults with advanced liver scarring (cirrhosis) from MASH, a fatty liver disease. The goal is to see if the drug can improve liver scarring and prevent the disease from getting worse. Participants will receive the drug or a…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug aims to reverse liver scarring in MASH patients
Disease control Recruiting nowThis study tests a new medicine called pegozafermin in adults with MASH (a type of fatty liver disease) and moderate liver scarring. About 1350 people will receive one of two doses of the drug or a placebo for 52 weeks. The goal is to see if the drug can improve scarring without …
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC